Recent Updates
Recently added Catalysts

Lamotrigine Dispersible/Chewable

Phase 1

Epilepsy | Small molecule | Neurology |GSK plc|Last Updated: Jun 1, 2017

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedCONTROLLED
Total Trials2
Total Enrollment162

FDA Designations

No designations recorded

Clinical trial landscape

Lamotrigine Dispersible/Chewable · 2 trials · 1 indication

Phase 1 2
NCT02064465The Bioequivalence Study of Lamotrigine Dispersible/Chewable Tablets 100mg Compared With Compressed Tablet 100 mgEpilepsy
COMPLETED138 Analytics
NCT01879423The Bioequivalence Study of Lamotrigine Dispersible/Chewable Tablets 5mg×5 Compared With Lamotrigine Compressed Tablet 25mg in Chinese Healthy Male SubjectsEpilepsy
COMPLETED24 Analytics
PHASE1COMPLETED
The Bioequivalence Study of Lamotrigine Dispersible/Chewable Tablets 100mg Compared With Compressed Tablet 100 mg
EpilepsyUnlock trial analytics
PHASE1COMPLETED
The Bioequivalence Study of Lamotrigine Dispersible/Chewable Tablets 5mg×5 Compared With Lamotrigine Compressed Tablet 25mg in Chinese Healthy Male Subjects
EpilepsyUnlock trial analytics

Study Endpoints

Primary Endpoints

Area under the concentration-time curve [AUC(0-inf)] of lamotrigine if coefficients of variation (CV)% of λz<=30%, or AUC(0-inf)• λz if CV% of λz >30%, or AUC(0-t) if AUC(0-inf) cannot be accurately determined, including bioequivalence evaluation
pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, 168, 216 hours post-dose
The observed maximum serum drug concentration (Cmax), including bioequivalence evaluation
pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, 168, 216 hours post-dose
Area under the concentration-time curve from time zero to infinity [AUC(0-inf)], including bioequivalence evaluation
pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, 168 hours post-dose

AUC(0-inf) is a measure of systemic drug exposure, which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample. AUC(0-inf) is defined as area under the concentration vs. time curve from zero to infinity.

Area under the concentration-time curve up to the last time point at which the concentration is above the lower limit of quantification [AUC(0-t)], including bioequivalence evaluation
pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, 168 hours post-dose

AUC(0-t) is a measure of systemic drug exposure, which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample. AUC(0-t) is defined as AUC from time 0 to the last data point above the Lower Limit of Quantification.

Secondary Endpoints

Time to reach Cmax (Tmax) as data permit.
pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, 168, 216 hours post-dose
Elimination half-time (t1/2) as data permit
pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, 168, 216 hours post-dose
Elimination rate constant, linear regression according to linear serum drug concentration-time curve (λz) as data permit.
pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, 168, 216 hours post-dose
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingNONE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Lamotrigine Dispersable/ChewableEXPERIMENTALlamotrigine dispersible/chewable tablet 100mg
Lamotrigine CompressedEXPERIMENTALlamotrigine compressed tablet 100mg
Lamotrigine (Lamictal) D/C 5mg*5, CrossoverEXPERIMENTALSingle dose of lamotrigine dispersible/chewable (D/C)5mg\*5 tablets at Day1 and Single dose of Lamotrigine Compressed 25mg\*1 tablet at Day15
Lamotrigine (Lamictal) Compressed 25mg, CrossoverEXPERIMENTALSingle dose of lamotrigine compressed 25mg\*1 tablet at Day1 and Single dose of lamotrigine dispersible/chewable 5mg\*5 tablets at Day15

Interventions

NameTypeDescription
Lamotrigine Dispersible/Chewable tabletDRUGSingle dose of lamotrigine dispersible/chewable 100mg tablet at Day1
Lamotrigine Compressed tabletDRUGSingle dose of lamotrigine compressed 100mg tablet at Day1
Lamotrigine Dispersible/Chewable tablets 5mg*5DRUGSingle dose of lamotrigine dispersible/chewable 5mg\*5 tablets at Day1 and Single dose of Lamotrigine Compressed 25mg\*1 tablet at Day15
Lamotrigine Compressed tablet 25mgDRUGSingle dose of lamotrigine compressed 25mg\*1 tablet at Day1 and Single dose of lamotrigine dispersible/chewable 5mg\*5 tablets at Day15
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 45 Years
SexMALE
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: * Healthy Chinese male non-smoker, based on medical history and physical examination, aged between 18 and 45 years of age inclusive, at the time of signing the informed consent. * Healthy as determined by a responsible and experienced physician, based on a medical evaluation inc...

Countries:China
Unlock Eligibility Criteria